熊去氧胆酸联合多潘立酮或莫沙必利治疗原发性胆汁反流性胃炎的疗效分析

Efficiency analysis of ursodeoxycholic acid combined with domperidone or mosapride in treatment of patients with primary bile reflux gastritis

目的比较熊去氧胆酸联合多潘立酮或联合莫沙必利治疗原发性胆汁反流性胃炎(PBRG)的疗效。方法选取2017年5月—2018年8月收治的PBRG患者86例,随机分为A组与B组各43例。A组采用熊去氧胆酸联合多潘立酮治疗,B组采用采用熊去氧胆酸联合莫沙必利治疗。治疗1个月后,比较2组临床疗效、临床症状评分以及不良反应发生情况。结果 A组总有效率为83. 72%,高于B组的76. 74%,差异无统计学意义(P> 0. 05)。治疗1个月后,2组腹痛、饱胀、恶心、呕吐等临床症状评分较治疗前明显下降,且A组上述症状评分均低于B组,但差异无统计学意义(P> 0. 05)。A组不良反应发生率为9. 30%,低于B组的13. 95%,差异无统计学意义(P> 0. 05)。结论熊去氧胆酸联合多潘立酮或莫沙必利治疗PBRG患者安全有效,能明显改善患者胃部不适症状,且不良反应较少且轻微。

Objective To compare the efficiency of ursodeoxycholic acid combined with domperidone or mosapride in the treatment of patients with primary bile reflux gastritis(PBRG).Methods Totally 86 patients with PBRG from May 2017 to August 2018 were selected and randomly divided into group A and group B43 cases in each group.Group A was treated with ursodeoxycholic acid combined with domperidone,while group B was treated with ursodeoxycholic acid combined with mosapride.After one month of treatment,the clinical efficiency,scores of clinical symptoms and incidence of adverse reactions were compared between the two groups.Results The total effective rate in group A was 83.72%,which was higher than 76.74%in group B(P>0.05).One month after treatment,the scores of clinical symptoms such as abdominal pain,fullness,nausea and vomiting were obviously lower than those before treatment in both groups,and the scores of the above symptoms in group A were lower than those in group B(P>0.05).The incidence rate of adverse reactions in group A was 9.30%,which was lower than 13.95%in group B(P>0.05).Conclusion Ursodeoxycholic acid combined with domperidone or mosapride is safe and effective in the treatment of patients with PBRG,which can obviously improve the gastric discomfort symptoms,and the adverse reactions are less and mild.